このページの翻訳は実験的なもので、現在開発中です。お待ちしております

DaVita マネジメント

マネジメント基準チェック /34

DaVita'sの CEO はJavier Rodriguezで、 Jun2019年に任命され、の在任期間は 5.17年です。の年間総報酬は$ 6.71Mで、 21%給与と79%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.84%を直接所有しており、その価値は$ 107.12M 。経営陣と取締役会の平均在任期間はそれぞれ5.6年と4年です。

主要情報

Javier Rodriguez

最高経営責任者

US$6.7m

報酬総額

CEO給与比率	21.0%
CEO在任期間	5.3yrs
CEOの所有権	1.0%
経営陣の平均在職期間	5.7yrs
取締役会の平均在任期間	4.1yrs

経営陣の近況

Recent updates

CEO報酬分析

DaVita の収益と比較して、Javier Rodriguez の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	US$860m
Mar 31 2024	n/a	n/a	US$816m
Dec 31 2023	US$7m	US$1m	US$692m
Sep 30 2023	n/a	n/a	US$596m
Jun 30 2023	n/a	n/a	US$454m
Mar 31 2023	n/a	n/a	US$500m
Dec 31 2022	US$3m	US$1m	US$547m
Sep 30 2022	n/a	n/a	US$680m
Jun 30 2022	n/a	n/a	US$834m
Mar 31 2022	n/a	n/a	US$903m
Dec 31 2021	US$3m	US$1m	US$978m
Sep 30 2021	n/a	n/a	US$984m
Jun 30 2021	n/a	n/a	US$883m
Mar 31 2021	n/a	n/a	US$791m
Dec 31 2020	US$73m	US$1m	US$783m
Sep 30 2020	n/a	n/a	US$832m
Jun 30 2020	n/a	n/a	US$824m
Mar 31 2020	n/a	n/a	US$816m
Dec 31 2019	US$17m	US$1m	US$705m
Sep 30 2019	n/a	n/a	US$623m
Jun 30 2019	n/a	n/a	US$548m
Mar 31 2019	n/a	n/a	US$551m
Dec 31 2018	US$8m	US$900k	US$616m
Sep 30 2018	n/a	n/a	US$617m
Jun 30 2018	n/a	n/a	US$698m
Mar 31 2018	n/a	n/a	US$652m
Dec 31 2017	US$8m	US$900k	US$909m

報酬と市場: Javierの総報酬 ($USD 6.71M ) は、 UK市場 ($USD 5.83M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Javierの報酬は過去 1 年間で 20% 以上増加しました。

CEO（最高経営責任者

Javier Rodriguez (53 yo)

5.3yrs

在職期間

US$6,712,328

報酬

Mr. Javier J. Rodriguez serves as an Independent Director at Gilead Sciences, Inc. since June 15, 2020. He has been Chief Executive Officer and Executive Director of DaVita Inc. since June 1, 2019. Mr. Rod...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Javier Rodriguez	CEO & Executive Director	5.3yrs	US$6.71m	1.0% $ 135.9m
Joel Ackerman	CFO & Treasurer	7.6yrs	US$6.87m	0.11% $ 15.1m
Kathleen Waters	Chief Legal & Public Affairs Officer	8.3yrs	US$5.61m	0.069% $ 9.4m
James Hearty	Chief Compliance Officer	6.5yrs	US$2.73m	0.014% $ 2.0m
Michael Staffieri	Chief Operating Officer Emeritus	10.5yrs	US$10.42m	0.19% $ 25.9m
David Maughan	Chief Operating Officer	no data	データなし	データなし
Christopher Berry	Group VP & Chief Accounting Officer	1.1yrs	データなし	データなし
Madhu Narasimhan	Chief Information Officer	less than a year	データなし	データなし
Nic Eliason	Group Vice President of Investor Relations	no data	データなし	データなし
Misha Palecek	Chief Transformation Officer of U.S. Kidney Care Business	no data	データなし	データなし
Jeffrey Giullian	Chief Medical Officer of Kidney Care	4.6yrs	データなし	データなし
Partha Das	Chief Medical Officer of DaVita International	6.1yrs	データなし	データなし

5.7yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: 0I7Eの経営陣は経験豊富で経験豊富です（平均在職期間は5.6年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Javier Rodriguez	CEO & Executive Director	5.3yrs	US$6.71m	1.0% $ 135.9m
Charles Berg	Director	17.5yrs	US$322.46k	0.031% $ 4.2m
Barbara Desoer	Independent Director	8.9yrs	US$384.96k	0.014% $ 1.9m
Phyllis Yale	Independent Director	8.2yrs	US$374.96k	0.019% $ 2.5m
Wendy Schoppert	Independent Director	1.2yrs	US$106.86k	0.0018% $ 246.4k
Pamela Arway	Independent Chair	15.3yrs	US$497.46k	0.029% $ 4.0m
Dennis Pullin	Independent Director	less than a year	データなし	0.00036% $ 49.0k
Adam Schechter	Independent Director	2yrs	US$334.96k	0.0040% $ 539.1k
Jason Hollar	Independent Director	2.3yrs	US$364.96k	0.0050% $ 687.5k
Gregory Moore	Independent Director	3yrs	US$355.89k	0.0065% $ 883.5k

4.1yrs

平均在職期間

61.5yo

平均年齢

経験豊富なボード: 0I7Eの取締役会は経験豊富であると考えられます ( 5年の平均在任期間)。

DaVita マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

CEO & Executive Director recently sold US$9.9m worth of stock

DaVita Announces Executive Appointments, Effective September 15, 2024

CEO & Executive Director recently sold US$6.3m worth of stock

Chief Legal & Public Affairs Officer recently sold US$1.1m worth of stock

Independent Director recently sold US$698k worth of stock

DaVita Appoints Madhu Narasimhan as Chief Information Officer, Effective June 3, 2024

Recent updates

CEO & Executive Director recently sold US$9.9m worth of stock

DaVita Announces Executive Appointments, Effective September 15, 2024

CEO & Executive Director recently sold US$6.3m worth of stock

New major risk - Revenue and earnings growth

Chief Legal & Public Affairs Officer recently sold US$1.1m worth of stock

Second quarter 2024 earnings released: EPS: US$2.56 (vs US$1.96 in 2Q 2023)

Now 21% overvalued

DaVita Inc. to Report Q2, 2024 Results on Aug 06, 2024

Now 20% overvalued after recent price rise

Now 20% overvalued after recent price rise

Now 20% overvalued after recent price rise

Independent Director recently sold US$698k worth of stock

DaVita Appoints Madhu Narasimhan as Chief Information Officer, Effective June 3, 2024

New major risk - Financial position

DaVita Inc., Annual General Meeting, Jun 06, 2024

High number of new directors

DaVita Inc. to Report Q1, 2024 Results on May 02, 2024

Davita Announces Dennis Pullin to Its Board of Directors

Chief Compliance Officer recently sold US$3.0m worth of stock

Full year 2023 earnings released: EPS: US$7.62 (vs US$5.88 in FY 2022)

DaVita Inc. to Report Q4, 2023 Results on Feb 13, 2024

Investor sentiment improves as stock rises 15%

New major risk - Financial position

Third quarter 2023 earnings released: EPS: US$2.70 (vs US$1.16 in 3Q 2022)

DaVita Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 21%

New major risk - Financial position

Second quarter 2023 earnings released: EPS: US$1.96 (vs US$2.38 in 2Q 2022)

DaVita Inc. Announces Management Changes

DaVita Inc. to Report Q2, 2023 Results on Aug 03, 2023

Chief Legal & Public Affairs Officer recently sold US$1.0m worth of stock

First quarter 2023 earnings released: EPS: US$1.28 (vs US$1.68 in 1Q 2022)

Director recently sold US$108k worth of stock

Full year 2022 earnings released: EPS: US$5.88 (vs US$9.30 in FY 2021)

DaVita Inc. to Report Q4, 2022 Results on Feb 22, 2023

Independent Director recently bought US$356k worth of stock

Second quarter 2022 earnings released: EPS: US$2.38 (vs US$2.76 in 2Q 2021)

Investor sentiment deteriorated over the past week

DaVita Inc. to Report Q3, 2022 Results on Oct 28, 2022

DaVita Inc. Appoints Adam H. Schechter to Board of Directors

Second quarter 2022 earnings released: EPS: US$2.38 (vs US$2.76 in 2Q 2021)

DaVita Inc. to Report Q2, 2022 Results on Aug 01, 2022

Chief Operating Officer of Kidney Care recently bought US$1.6m worth of stock

Independent Director recently sold US$226k worth of stock

DaVita Inc., Annual General Meeting, Jun 09, 2022

First quarter 2022 earnings released: EPS: US$1.68 (vs US$2.18 in 1Q 2021)

DaVita Inc. to Report Q1, 2022 Results on May 05, 2022

DaVita Inc. Appoints Jason M. Hollar as Independent Director

Independent Director recently sold US$80k worth of stock

DaVita Inc. (NYSE:DVA) acquired 17 Dialysis Centers in United States.

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

DaVita Inc. to Report Q4, 2021 Results on Feb 10, 2022

DaVita Inc. (NYSE:DVA) acquired MedSleuth, Inc.

Third quarter 2021 earnings released: EPS US$2.48 (vs US$1.31 in 3Q 2020)

Independent Director recently sold US$105k worth of stock

Second quarter 2021 earnings released: EPS US$2.76 (vs US$1.65 in 2Q 2020)

DaVita Inc. (NYSE:DVA) acquired a Dialysis Center in US.

Davita's China Affiliate to Invest in Hunan Fangsheng Pharma's Unit for 31.7% Stake

First quarter 2021 earnings released: EPS US$2.18 (vs US$1.84 in 1Q 2020)

Revenue misses expectations

Full year 2020 earnings released: EPS US$6.54 (vs US$4.61 in FY 2019)

Kyros Law Files Legal Claims on Behalf of Davita Inc Investors

DaVita Inc. to Report Q4, 2020 Results on Feb 11, 2021

Renalytix AI plc and DaVita Announce Partnership

DaVita Inc. Announces Management Changes, with Effect from December 15, 2020

Chief Legal Officer recently sold US$1.1m worth of stock

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

マネジメント基準チェック /34